Ranibizumab injection

July 17, 2018

Ranibizumab injection

What is this medicine?

RANIBIZUMAB (RA ni BIZ oo mab) is an injectable medicine for the eye. It is used to treat certain types of disease that affect the retina and blood vessels in the eye. This medicine helps to slow the disease and may help to maintain vision. It is not a cure.

How should I use this medicine?

This medicine is injected into the eye. It is given by an ophthalmologist (eye doctor) who specializes in this treatment.

Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.

What side effects may I notice from receiving this medicine?

Side effects that you should report to your doctor or health care professional as soon as possible:

  • allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue

  • changes in vision

  • eye that is red, sensitive to light, or painful

  • problems with balance, talking, or walking

Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):

  • body aches, pains

  • dry eyes

  • headache

  • nausea

  • runny or stuffy nose

What may interact with this medicine?

  • verteporfin

What if I miss a dose?

This does not apply.

Where should I keep my medicine?

This drug is given in a hospital or clinic and will not be stored at home.

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:

  • eye infection

  • glaucoma

  • prior eye procedure or surgery

  • an unusual or allergic reaction to ranibizumab, other medicines, foods, dyes, or preservatives

  • pregnant or trying to get pregnant

  • breast-feeding

What should I watch for while using this medicine?

Tell your doctor or healthcare professional if your symptoms do not start to get better or if they get worse. Regular eye exams will be needed while you are being treated with this medicine.

Updated:  

July 17, 2018